Association Between
            <i>Tnf-α</i>
            (-308 A/G, -238 A/G, -857 C/T) Polymorphisms and Responsiveness to Tnf-α Blockers in Spondyloarthropathy, Psoriasis and Crohn’S Disease: A Meta-Analysis

Song, Gwan Gyu; Seo, Young Ho; Kim, Jae Hoon; Choi, Sung Jae; Ji, Jong Dae; Lee, Young Ho

doi:10.2217/pgs.15.90

Cited by 45 publications

(41 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, body mass index predicts poor response and long‐term efficacy to conventional and biological treatments . Specific TNFAIP3 single nucleotide polymorphisms have been associated with a higher response rate to etanercept and adalimumab . Similarly, IL‐17A and IL‐17F single nucleotide polymorphisms predict a higher response to ustekinumab, infliximab or adalimumab .…”

Section: Resultsmentioning

confidence: 99%

“…36,37 Specific TNFAIP3 single nucleotide polymorphisms have been associated with a higher response rate to etanercept and adalimumab. 38 Similarly, IL-17A and IL-17F single nucleotide polymorphisms predict a higher response to ustekinumab, infliximab or adalimumab. 39 Finally, a faster and higher response to ustekinumab has been reported in HLA-Cw6-positive patients.…”

Section: Treatments Goalsmentioning

confidence: 99%

See 1 more Smart Citation

Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis

Gisondi

Altomare

Ayala

et al. 2017

Acad Dermatol Venereol

155

159

View full text Add to dashboard Cite

Psoriasis is a common disease, which has a considerable impact on the healthcare system. Therefore, appropriate use of therapeutic resources is very important. Management of psoriasis in daily clinical practice is highly variable because many issues are still debated and not definitely addressed by the evidence-based medicine. Moreover, the different availability and reimbursability of drugs in each country justifies national guidelines. Expert consensus can provide helpful guidelines for optimizing patient care. A total of 20 dermatologists from different areas of Italy and with large experience in the treatment of psoriasis agreed to participate in the guidelines expert panel who aimed to reach consensus on the factors influencing psoriasis severity, the indications for systemic treatments, the parameters to be considered in the choice of treatment, and the factors to be considered in the choice of biological treatment. The recommendations for the use, screening and monitoring of systemic therapies were based on the 2015 S3 European Dermatology Forum/European Academy of Dermatology and Venereology psoriasis guidelines. Recommendations on the treatment of psoriasis in special patient populations were also agreed. The final document was discussed in a meeting moderated by a facilitator with participation of the entire group and adopting a nominal group technique to reach consensus. A statement was regarded as consented when agreement was achieved by at least 75% of the voting experts according to the Delphi procedure.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Treatments Goalsmentioning

confidence: 99%

Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis

Gisondi

Altomare

Ayala

et al. 2017

Acad Dermatol Venereol

155

159

View full text Add to dashboard Cite

show abstract

“…There are several important differences between the present study and two related meta-analyses that had been published previously3536. In the present study, we included more patients than either of the two previous studies and added a set of unpublished data from our lab.…”

Section: Discussionmentioning

confidence: 94%

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis

Liu

Zheng

Zhu

et al. 2016

Sci Rep

View full text Add to dashboard Cite

While previous studies have researched in association analyses between TNFα promoter polymorphisms and responses to TNF blockers in spondyloarthritis patients, their results were conflicting. Therefore, we aimed to determine whether TNFα promoter polymorphisms could predict response to TNF blockers and find the source of heterogeneity. Data were extracted and analyzed from published articles and combined with our unpublished data. We found that the greatest potential sources of heterogeneity in the results were gender ratio, disease type, continents, and TNF blockers. Then Stratification analysis showed that the TNFα −308 G allele and the −238 G allele predicted a good response to TNF blockers (OR = 2.64 [1.48–4.73]; 2.52 [1.46–4.37]). However, G alleles of TNFα −308 and −238 could predict the response to etanercept (OR = 4.02 [2.24–7.23]; 5.17 [2.29–11.67]) much more powerfully than the response to infiliximab/adalimumab (OR = 1.68 [1.02–2.78]; 1.28 [0.57–2.86]). TNFα −857 could not predict the response in either subgroup. Cumulative meta-analysis performed in ankylosing spondylitis patients presented the odds ratio decreased with stricter response criteria. In conclusion, TNFα −308 A/G and −238 A/G are more powerful to predict the response to Etanercept and it is dependent on the criteria of response.

show abstract

“…Song et al . performed a meta‐analysis for this single‐nucleotide polymorphism (SNP) but did not include both of the aforementioned studies . Rather, they combined the study by Vasilopoulos et al .…”

Section: Resultsmentioning

confidence: 99%

A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis

et al. 2017

View full text Add to dashboard Cite

show abstract

Association Between Tnf-α (-308 A/G, -238 A/G, -857 C/T) Polymorphisms and Responsiveness to Tnf-α Blockers in Spondyloarthropathy, Psoriasis and Crohn’S Disease: A Meta-Analysis

Abstract: Individuals carrying the TNF-α -308 G, -238 G, or -857 C common alleles show better responses to TNF-α blockers than those with minor alleles in Caucasians.

Cited by 45 publications

References 36 publications

Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis

Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis

A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis

Contact Info

Product

Resources

About